Introduction : HCV infection is not only a risk factor for HCC, but also closely related to recurrence after HCC treatment. Currently, worldwide treatment of HCV infection is being developed, among which DAA has become a more effective treatment than conventional interferon + ribavirin therapy. Because of the importance of HCV therapy in patients who undergo liver transplantation, this study aims to evaluate the efficacy of DAA in liver transplant recipients due to HCV related HCC.

Methods : In this study, 42 patients were enrolled who received liver transplantation at Seoul National University Hospital and treated with DAA for chronic HCV infection from July 2015 to August 2017. We retrospectively analyzed the results of the study and found that the sustained viral response (SVR), which was not associated with the re - proliferation of the virus for 24 weeks after treatment, was considered to be effective.

Results : Of the 42 subjects included in the study, 39 had achieved SVR, or remained unresponsive to the virus until August 2017. One of the patients who had experienced reactivation of the virus after the treatment was found to have recurrence of HCC 12 weeks after the start of treatment. Virus regrowth was observed 4 weeks after the end of treatment. HCV

Conclusions : If possible, it is advisable to perform HCV treatment before receiving a liver transplantation.